Kimryn Rathmell: My editorial with Dr. Catherine Fahey highlighting a recent study by Dr. Joseph Unger
Kimryn Rathmell shared on X/Twitter:
“A recent study by Dr. Joseph Unger, Fred Hutchinson Cancer Center + team provides an updated estimate of cancer Clinical Trial enrollment. The good news? More patients are participating in Cancer Research than previously thought.
Here’s my accompanying Journal of Clinical Oncology editorial with Dr. Catherine Fahey, Vanderbilt University Medical Center highlighting this work, where we are currently, and where the field needs to grow with respect to clinical trial access and accrual.”
Source: Kimryn Rathmell/X
Dr. Kimryn Rathmell is a distinguished leader and researcher in the field of kidney cancer. Specializing in the research and treatment of complex and hereditary kidney cancers.
She has held leadership positions with organizations such as the American Society of Clinical Oncology and the American Society for Clinical Investigation, she has been elected to esteemed academies including the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.
Currently serving as the director of the National Cancer Institute, Dr. Rathmell continues to lead research initiatives and advance the understanding and treatment of kidney cancer, ultimately improving the lives of patients worldwide.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023